Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studies environmental factors and liver cancer risk in people with cirrhosis

Collects blood, urine and stool samples from adults with cirrhosis.

Key facts

Who runs it
University Hospital, Angers
Where
Angers, Rennes, and Tours, FranceSee the 4 sites
Trial code
Registry title
ProspEXPO : Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome
Status
Recruiting
People taking part
300 people, planned
Started
17 Dec 2025
Expected to end
Mar 2029
Type of study
Interventional, 2 groups
Treatments tested
  • Blood, urine and stool biocollection
Record updated
10 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with fatty liver disease (metabolic or alcohol-related) and cirrhosis, with or without liver cancer. Samples are collected to study how lifestyle and environment relate to liver cancer.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Cirrhosis from metabolic and/or alcohol-related fatty liver disease (MASLD, ALD or MetALD). One group has cirrhosis only; the other group has liver cancer (HCC) within cirrhosis. A liver biopsy was done in the last 2 months or is planned.

Main reasons for not taking part

  • Chronic liver disease from causes other than MASLD, ALD or MetALD
  • Cirrhosis complications in the 2 years before joining (ascites, hepatic encephalopathy, bleeding from varices, liver failure, hepatorenal syndrome)
  • History of liver cancer (for the group without liver cancer)
  • Pregnant, breast-feeding or women giving birth
  • People deprived of liberty by judicial or administrative decision

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Presence of metabolic and/or alcoholic steatotic liver disease, as defined by the new nomenclature (MASLD, ALD, or mixed MetALD)
  • Liver biopsy performed (less than 2 months ago) or planned as part of treatment for diagnosis of cirrhosis ("Control" group without HCC) or diagnosis of HCC on cirrhosis ("Case" group)
  • Patient affiliated to or benefiting from a social security scheme
  • Patient having signed an informed consent to participate in the study (bio-collection)

Who cannot take part

  • Decompensation of cirrhosis in the two years prior to inclusion (ascites, hepatic encephalopathy, gastrointestinal variceal hemorrhage, liver failure, hepatorenal syndrome)
  • Causes of chronic liver disease other than MASLD, ALD, or MetALD
  • For the "Control" group: history of hepatocellular carcinoma
  • Pregnant, breast-feeding or parturient women
  • Persons deprived of liberty by judicial or administrative decision

Where in France

  • Angers University HospitalAngers, FranceContact: Jérôme BOURSIER, ProfessorTaking people
  • Centre Eugène Marquis (Oncology center)Rennes, FranceContact: Julien EDELINENot yet recruiting
  • Rennes University Hospital, Hepatogastroenteroly DepartmentRennes, FranceContact: Edouard BARDOU-JACQUETNot yet recruiting
  • Tours University Hospital, HepatoGastroenterology DepartmentTours, FranceContact: Laure ELKRIEFNot yet recruiting

About the trial

What the trial wants to find out

The aim of the study is to build up a bio-collection of biological samples from patients with cirrhosis. Further work using this bio-collection will permit to describe the influence of different exposome factors (nutrition, physical activity, socio-demographic conditions, tobacco, alcohol, pollutants) on the occurrence of the main type of liver cancer (called HCC).

Read full original descriptionShow less

Indeed, in the vast majority of cases, HCC develops within cirrhosis, and the factors that precipitate the progression of cirrhotic patients to HCC remain largely unknown.

The 2 groups in the trial

  • Control groupOther group

    Group of patients with MASLD and/or ALD at cirrhosis stage, without HCC

    Treatment: Blood, urine and stool biocollection

  • Case groupOther group

    Group of patients with MASLD and/or ALD at cirrhosis stage and complicated by HCC

    Treatment: Blood, urine and stool biocollection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
ProspEXPO : PROSPective Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome
Plain-language title
Studies environmental factors and liver cancer risk in people with cirrhosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 June 2026